Tools   Select Another Resource Report Type

http://psychology-tools.com/pas/

Assessment scale to measure the severity of illness in patients with panic disorder (with or without agoraphobia). It is available in both clinician-administered and self-rating formats. It contains 5 sub-scales: panic attacks, agoraphobic avoidance, anticipatory anxiety, disability, and functional avoidance (health concerns). It rates the severity of symptoms over the past week.

Proper citation: Panic and Agoraphobia Scale (RRID:SCR_003667) Copy   

•   Source: SciCrunch Registry

http://www.hawkesbay.health.nz/file/fileid/47359

Assessment scale commonly used in hospitals to determine the anxiety and depression levels that a patient is experiencing. It contains 14 items, 7 of which are questions about anxiety and the other 7 are about depression.

Proper citation: Hospital Anxiety and Depression Scale (RRID:SCR_003665) Copy   

•   Source: SciCrunch Registry

http://www.help4adhd.org/documents/adultadhdselfreportscale-asrs-v1-1.pdf

A self reporting scale to assess if adult patients are suffering from symptoms of attention deficit-hyperactivity disorder (ADHD). The Symptom Checklist is an instrument consisting of the eighteen DSM-IV-TR criteria. Six of the eighteen questions were found to be the most predictive of symptoms consistent with ADHD. These six questions are the basis for the ASRS v1.1 Screener and are also Part A of the Symptom Checklist. Part B of the Symptom Checklist contains the remaining twelve questions.

Proper citation: Adult ADHD Self-Report Scale (RRID:SCR_003663) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/research/ki-biobank

KI Biobank is an accredited core facility offering sample collection services. KI Biobank is located at the Department of Medical Epidemiology and Biostatistics. KI Biobank offer infrastructure for pre analytical sample handling and provide researchers guidance on how samples should be taken and labeled. The processes comprise registration, handling, storage and distribution of samples. KI Biobank also offers DNA-extraction from blood and saliva. In order to insure complete traceability on samples and belonging information all processes are controlled by a Laboratory Information Management System (LIMS). For every new study a contract is established describing the study and the disposition rights. We also help in writing Biobank agreements including multicenteravtal and Material Transfer Agreement. KI Biobank is, according to the Biobank law, responsible for all sample collections handled within the core facility and those that are stored on the departments on KI campus. Clinical sample collections are handled by the Biobank units at the respective hospitals within the Stockholm County Council. Besides the samples that are stored centrally at KI Biobank, KI Biobank is also the administrative biobank for research sample collections at Karolinska Institutet that are stored and administrated at the departments. All research sample collections must be reported to KI Biobank. The following types of sample collections are registered in the biobank; sample collections taken within the regular health care that has been transferred to Karolinska Institutet with an agreement of transfer, samples taken from healthy individuals or other persons out of the regular health care and samples that have been taken abroad.

Proper citation: Karolisnka Biobank (RRID:SCR_004355) Copy   

•   Source: SciCrunch Registry

http://www.wmt.com

An ISO 9001 certified designer, manufacturing and distributing orthopedic implants and instrumentation worldwide for over 50 years. Wright''s product offerings include large joint implants for the hip and knee; extremity implants for the shoulder, elbow, hand, wrist and foot; and both synthetic and tissue-based bone graft substitute materials. Since its inception, Wright has introduced a number of products that represent new standards in orthopedic technology. From new material technologies to advanced products and instrumentation, Wright is committed to finding solutions to the challenges that face today''s orthopedic professionals.

Proper citation: Wright Medical Technology, Inc. (RRID:SCR_004195) Copy   

•   Source: SciCrunch Registry

http://www.public-health.uiowa.edu/icmha/outreach/documents/bprs_expanded.pdf

Assessment scale to measure the psychiatric symptoms of patients who might have psychiatric symptoms including depression, anxiety, hallucinations, and strange or unusual behaviors. The symptoms of the patient are rated between 1 and 7 and then the 18-24 items/symptoms are scored and combined to create the final score of the patient. This scale is similar to the PANSS, SANS, and SAPS.

Proper citation: Brief Psychiatric Rating Scale (RRID:SCR_003657) Copy   

•   Source: SciCrunch Registry

https://www.msu.edu/course/sw/840/stocks/pack/axisv.pdf

THIS RESOURCE IS NO LONGER IN SERVICE.Documented on October 6th, 2022. Assessment scale that considers psychological, social, and occupational functioning (how well they handle various problems in life) on a hypothetical continuum of mental health-illness. This does not include impairment in functioning due to physical (or environmental) limitations. The score received is usually given as a range (0-100) to patients. Scoring: * 91-100 No Symptoms * 81-90 Absent/Minimal Symptoms * 71-80 Symptoms are Present * 61-70 Mild Symptoms * 51-60 Moderate Symptoms * 41-50 Serious Symptoms * 31-40 Some Impairment * 21-30 Influenced behavior by Delusions or Hallucinations * 11-20 Some Danger of Hurting Self or Others * 1-10 Persistent Danger of Hurting Self or Others * 0 Inadequate Information on Patient

Proper citation: Global Assessment of Functioning (RRID:SCR_003656) Copy   

•   Source: SciCrunch Registry

http://www.rbcsyd.se/

To meet the law requirements and regulations of the National Board of the Southern Health Care Region, Region Skane and Lund University agreed to establish a common biobanking center for Southern healthcare region. Regional biobanksrcentrum will develop and maintain systems for quality assurance and integrity protected using biobanks. The Regional Biobank center is responsible for matters relating to the collection, storage and use of samples stored in biobanks in the Southern healthcare region. Regional Biobank center operations consist of: * to promote the use of biobank material is in accordance with legal requirements biobank * to promote integrity protected and safe storage of repository material * to provide information about the biobank law and biobank materials used for individual sample donors, health professionals, researchers and the public * to handle requests for modified consent and desire to destroy or de test * maintaining a current and privacy protected records of repository material in the region * work to the individual''s integrity will be strengthened in relation to research on biobank material. Tissue samples available to other parties, by surrendering, or by sending tissue samples for analysis, requiring the return or destruction, after completion of the analysis. Regional Biobank Centre (RBC) for the southern healthcare region was established in 2004 and was until 2010 in the Oncology Centre. As of January 1, 2011 it is under the management of RBC Labmedicin Skane.

Proper citation: Swedish Regional Biobank (RRID:SCR_004503) Copy   

•   Source: SciCrunch Registry

http://psychology-tools.com/eat-26/

A widely used standardized self-report measure of symptoms and concerns characteristic of eating disorders. The original 40-item version was developed for a study to examine socio-cultural factors in the development and maintenance of eating disorders. A 26-item refinement of the original test has been made and it has been translated into many different languages and used in hundreds of studies. The EAT-26 has been useful as a screening tool to assess eating disorder risk in high school, college and other special risk samples such as athletes. It can be used in a non-clinical as well as a clinical setting not specifically focused on eating disorders. It can be administered in group or individual settings and is designed to be administered by mental health professionals, school counselors, coaches, camp counselors, and others with interest in gathering information to determine if an individual should be referred to a specialist for evaluation for an eating disorder. It is intended primarily for adolescents and adults. The EAT-26 should be used as the first step in a two-stage screening process. According to this methodology, individuals who score 20 or more on the test should be interviewed by a qualified professional to determine if they meet the diagnostic criteria for an eating disorder. The tests are rated on a six-point scale in response to how often the individual engages in specific behaviors. (adapted from Wikipedia)

Proper citation: Eating Attitudes Test (RRID:SCR_003695) Copy   

•   Source: SciCrunch Registry

http://www.tmf-ev.de/BiobankenRegisterEN/Registry.aspx?udt_2021_param_detail=72

It is the aim of the SepNet initiative to establish a central facility, essential to data and sample quality and homogeneity, that comprises a structured and easily accessible sample bank with probes of homogeneous quality originating from a well-characterized patient population enrolled in independent, innovative and internationally competitive prospective clinical sepsis trials. The SepNetBiobank is a core facility of SepNet. The object of this central sample resource is to organize and handle all relevant aspects of sampling, storage and delivery of samples in the SepNet collaboration to ensure homogeneity of the samples in terms of specimen quality and maintaining sampling standards. This will be achieved through central handling of samples collected in peripheral nationwide 17 regional centers and an additional 36 associated centers according to an agreed sampling scheme and pre-set standards for sample quality, sample handling and banking; quality assurance and all relevant parts of sample handling will be in the hands of the core unit, minimizing pre-analytical steps in the heterogeneous environment of the different regional centers. In the next few months a fully automated sample storage system will be implemented that allows handling of more than 200.000 individual aliquots expected after completion of the different ongoing and planned SepNet Trails. In the next six months a fully automated -80 degree C sample storage system will be implemented. After completion of the plannend and ongoing SepNet trials more than 59.710 expected primary samples (218.040 aliquots) will be stored in this system. This outstanding sample resource will provide the basis for scientific projects aming at improving patient care with sepsis e.g. advancement in diagnostics, risk stratification, therapy and outcome.

Proper citation: SepNet Central Sample Bank (RRID:SCR_004543) Copy   

•   Source: SciCrunch Registry

http://psychology-tools.com/zung-depression-scale/

A self-rating scale to assess the level of depression for patients diagnosed with depressive disorder. There are 20 items on the scale that rate the rating affective, psychological and somatic symptoms associated with depression. There are ten positively worded and ten negatively worded questions. Each question is scored on a scale of 1 through 4 (based on these replies: a little of the time, some of the time, good part of the time, most of the time). Scores on the test range from 20 through 80. The scores fall into four ranges: Scoring: * 20-44 Normal Range * 45-59 Mildly Depressed * 60-69 Moderately Depressed * 70 and above Severely Depressed The Zung Self-Rating Depression Scale has been translated into many languages, including Arabic, Azerbaijani, Dutch, German, Portuguese, and Spanish. (Adapted from Wikipedia)

Proper citation: Zung Self-Rating Depression Scale (RRID:SCR_003692) Copy   

•   Source: SciCrunch Registry

http://psychology-tools.com/altman-self-rating-mania-scale/

A 5-item self-reported diagnostic scale used to assess the presence and severity manic and hypomanic symptoms, most commonly in patients diagnosed with bipolar disorder. It assesses differences in normal or baseline levels in five subjective and behavioral areas: positive mood, self-confidence, sleep patterns, speech patterns / amount of sleep, and motor activity. Scores above a 5 are indicative of mania, or hypomania, with the severity of symptoms increasing with higher scores. Examining score changes over time is also used to determine the efficacy of a particular treatment in a clinical setting and to qualify whether the severity a manic episode is increasing or decreasing. (Adapted from Wikipedia) Scoring: * 0-5 Normal * 6-25 Probable Manic or Hypomanic Condition, Further Testing Recommended

Proper citation: Altman Self-Rating Mania Scale (RRID:SCR_003699) Copy   

•   Source: SciCrunch Registry

http://psychology-tools.com/montgomery-asberg-depression-rating-scale/

A ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms: 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts. Scoring: * 0-6 Normal/Symptom Absent * 7-19 Mild Depression * 20-34 Moderate Depression * >34 Severe Depression (Adapted from Wikipedia)

Proper citation: Montgomery-Asberg Depression Rating Scale (RRID:SCR_003690) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/AREDS/?SsId=68

The NEI-AREDS Genetic Repository is a collection of genetic material submitted by participants in the Age-Related Eye Disease Study (AREDS) which was sponsored by the National Eye Institute (NEI). The Repository stores DNA for use by investigators conducting genetics research into the causes of eye disease. The Age-Related Eye Disease Study was designed to learn about macular degeneration and cataract, two leading causes of vision loss in older adults. The study looked at how these two diseases progress and what their causes may be. In addition, the study tested certain vitamins and minerals to find out if they can help to prevent or slow these diseases. Participants in the study did not have to have either disease. (Enrollment was completed in January 1998.) Eleven medical centers in the United States took part in the study, and more than 4,700 people across the country were enrolled in AREDS. The study was supported by the National Eye Institute, part of the Federal government''s National Institutes of Health. The clinical trial portion of the study also received support from Bausch & Lomb Pharmaceuticals and was completed in October 2001. Data from AREDS is publicly available in the Database of Genotypes and Phenotypes (dbGaP). Genetic samples from 600 AREDS participants (200 controls, 200 Neovascular AMD cases, and 200 Geographic Atrophy cases) were selected using data available in March 2005 and then were genotyped using the Illumina 100K and the Affymetrix 100K gene chips. These genotype data are available in the dbGaP. DNA samples are distributed only to qualified professional persons who are associated with recognized research, medical, educational, or industrial organizations engaged in health-related research or health delivery. All orders for DNA samples must be submitted using the online catalog.

Proper citation: NEI-AREDS Genetic Repository (RRID:SCR_004536) Copy   

•   Source: SciCrunch Registry

http://www.seqwright.com/clinicaltrialservices/biorepository.html

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks, which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute''s (NCI''s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester''s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone., documented on August 17, 2021.Convenient, cost-effective and reliable storage solutions including maintaining, storing and monitoring your biological samples. Avoid costly purchases of ultra-low temperature freezers, sample tracking LIMS, and layers of emergency back-up infrastructure. Enjoy peace of mind in the knowledge that your critical samples are safe, secure, and readily available to you. Service Features * Real-time sample tracking and monitoring, with 24/7 accessibility. * GLP compliant repository with cold chain of custody. * Numerous storage options, from ambient temperature to -170 degrees C. * Hazardous specimen storage capabilities. * Redundant emergency back-up systems. * Secure-access facility. * At Temperature back-up freezers. * Rapid domestic & international shipping. As a full-service contract genomics provider, SeqWright is able to offer our BioRepository customers the additional benefit of a broad portfolio of regulated services for testing of samples, as and when required, and then returning the samples back to our BioRepository for further storage. Contact us for your customized solution.

Proper citation: SeqWright Biorepository (RRID:SCR_004657) Copy   

•   Source: SciCrunch Registry

http://www.seracare.com/OurProductsandServices/SampleStorageManagementandProcessing/tabid/159/Default.aspx

SeraCare stores and manages over 19 million samples in our state-of-the-art biobank, and is supported by a range of processing and characterization services. Security. Backup. On-line inventory. Next day sample access. Analysis. Characterization. Anonymization. Transformation. Restoration. Compliance. Coordination. We handle your samples all the way through. SeraCare is well-equipped to perform a wide range of sample storage, management, and processing services. We have longstanding customer relationships with clinical and research laboratories, biopharma, and public health agencies, including the National Institutes of Health, the Centers for Disease Control, and the US Food and Drug Administration. * Our scientists have expertise in virology, immunology, molecular biology, and biochemistry * We have a proven legacy of custom assay design and custom product development to meet your specifications

Proper citation: SeraCare Lifesciences: Sample Storage Management and Processing Services (RRID:SCR_004535) Copy   

•   Source: SciCrunch Registry

http://serene.me.uk/tests/ham-d.pdf

A multiple question assessment scale used to provide an indication of depression and serves as a way to evaluate recovery in patients. It is designed for adults and is used to rate the severity of their depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms. It was designed to be administered by a trained professional using a semi-structured interview. Although Hamilton's original scale had 17 items, other versions were developed to include up to 29 items (HRSD-29).(Adapted from Wikipedia) It takes about 20 minutes to complete the interview and score the results. Scoring: * 0-7 Normal * 8-13 Mild * 14-18 Moderate * 19-22 Severe * > or = 23 Very Severe

Proper citation: Hamilton Rating Scale for Depression (RRID:SCR_003686) Copy   

•   Source: SciCrunch Registry

http://crahw.anu.edu.au/files/English_long.pdf

Assessment questionnaire used as a screening test for dementia that is filled out by a relative or other supporter who knows the patient for a minimum of 10 years to determine whether that person has declined in cognitive functioning. It lists 26 everyday situations where a person has to use their memory or intelligence. The questions on the test compare the patient''s state of mind to 10 years ago using the scale of: Much Improved A Bit Improved Not Much Change A Bit Change A Bit Worse and Much Worse. If the person is found to have significant cognitive decline, then this needs to be followed up with a medical examination to determine whether dementia is present. Scoring: * 0-3 No Cognitive Impairment * >3 Cognitive Impairment

Proper citation: Informant Questionnaire on Cognitive Decline in the Elderly (RRID:SCR_003680) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/documents_custom/gpcog(english).pdf

Assessment test to screen a patient for cognitive impairment that takes less than four minutes for the cognitive test and less than two minutes for the informant interview. The cognitive test includes nine items: (1) time orientation, clock drawing: (2) numbering and spacing as well as (3) placing hands correctly, (4) awareness of a current news event and recall of a name and an address ( (5) first name, (6) last name, (7) number, (8) street, and (9) suburb). Each correct answer is valid one point leading to a maximum score of 9 (fewer points indicate more impairment). (Wikipedia) The informant interview asks six historical questions from an informant/next of kin who knows the patient well. He or she is asked to compare the patient's current function with his/her performance a few years ago. Areas that are covered in the informant interview include memory, word finding difficulties, trouble managing finances, difficulties managing medication independently and needing assistance with transportation. Scoring: * 9 No Significant Cognitive Impairment * 8-5 More Testing Required * 4-0 Cognitive Impairment

Proper citation: General Practitioner Assessment of Cognition (RRID:SCR_003679) Copy   

•   Source: SciCrunch Registry

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM380961.pdf

An electronically administered patient-reported outcome (PRO) measure that is a qualified measure of symptoms of acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease (ABECB-COPD), for use in phase 2 trials. Refer to the proposed context of use, http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM399682.pdf. Its intent to quantify frequency, severity, and duration of acute exacerbations in clinical trials of COPD including those with chronic bronchitis. It is designed as an electronic diary made up of fourteen items to be completed by the patient each evening just prior to bedtime. (An item-reduction statistical analysis narrowed the questions from 23 to 14.) For more information see, http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/UCM386248.pdf

Proper citation: Exacerbations of Chronic Pulmonary Disease Tool (RRID:SCR_003718) Copy   

•   Source: SciCrunch Registry